• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection.无需致死预处理诱导的混合嵌合体可防止T细胞和抗α1,3半乳糖介导的移植物排斥反应。
J Clin Invest. 1999 Aug;104(3):281-90. doi: 10.1172/JCI6656.
2
Tolerization of Gal alpha 1,3Gal-reactive B cells in pre-sensitized alpha 1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism.通过非清髓性诱导混合嵌合体使预先致敏的α1,3-半乳糖基转移酶缺陷小鼠中Galα1,3Gal反应性B细胞产生耐受。
Xenotransplantation. 2001 Nov;8(4):227-38. doi: 10.1034/j.1399-3089.2001.00006.x.
3
T cell and B cell tolerance to GALalpha1,3GAL-expressing heart xenografts is achieved in alpha1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism.在α1,3-半乳糖基转移酶缺陷小鼠中,通过非清髓性诱导混合嵌合体,可实现T细胞和B细胞对表达α1,3-半乳糖(GALα1,3GAL)的心脏异种移植物的耐受。
Transplantation. 2001 Jun 15;71(11):1532-42. doi: 10.1097/00007890-200106150-00009.
4
Sequential analysis of anti-alpha Gal natural antibody-producing B cells in GalT knockout mice in cyclophosphamide-induced tolerance.环磷酰胺诱导耐受的GalT基因敲除小鼠中抗α半乳糖天然抗体产生B细胞的序列分析
Scand J Immunol. 2006 Jun;63(6):435-43. doi: 10.1111/j.1365-3083.2006.001763.x.
5
Application of cyclophosphamide-induced tolerance in alpha1,3-galactosyltransferase knockout mice presensitized with Gal alpha 1-3Gal beta-4-GlcNAc antigens.环磷酰胺诱导的耐受性在预先用Galα1-3Galβ-4-GlcNAc抗原致敏的α1,3-半乳糖基转移酶基因敲除小鼠中的应用。
Surg Today. 2008;38(9):807-14. doi: 10.1007/s00595-007-3715-1. Epub 2008 Aug 28.
6
Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.使用去除T细胞的抗体、环磷酰胺和胸腺照射进行非清髓性预处理后诱导稳定的长期混合造血嵌合状态,可导致供体特异性的体外和体内耐受。
Biol Blood Marrow Transplant. 2001;7(12):646-55. doi: 10.1053/bbmt.2001.v7.pm11787527.
7
Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism.通过诱导混合嵌合体来使抗Galα1-3Gal天然抗体形成B细胞产生耐受。
J Exp Med. 1998 Apr 20;187(8):1335-42. doi: 10.1084/jem.187.8.1335.
8
Differing mechanisms of early and late B cell hyporesponsiveness induced by mixed chimerism.混合嵌合体诱导的早期和晚期B细胞低反应性的不同机制。
Am J Transplant. 2005 Dec;5(12):2821-9. doi: 10.1111/j.1600-6143.2005.01121.x.
9
Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.额外的单克隆抗体(mAB)注射可以替代胸腺照射,从而在经抗T细胞mAB和3戈瑞全身照射预处理后接受骨髓移植的小鼠中诱导混合嵌合体形成和耐受。
Transplantation. 1996 Feb 15;61(3):469-77. doi: 10.1097/00007890-199602150-00027.
10
Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens.预防小鼠心脏同种异体移植中的慢性排斥反应:基于嵌合和非嵌合诱导共刺激阻断的免疫耐受诱导方案的比较
J Immunol. 2002 Sep 1;169(5):2677-84. doi: 10.4049/jimmunol.169.5.2677.

引用本文的文献

1
Physiological basis for xenotransplantation from genetically modified pigs to humans.异种移植供体猪的基因修饰的生理基础。
Physiol Rev. 2024 Jul 1;104(3):1409-1459. doi: 10.1152/physrev.00041.2023. Epub 2024 Mar 22.
2
Progress in islet xenotransplantation: Immunologic barriers, advances in gene editing, and tolerance induction strategies for xenogeneic islets in pig-to-primate transplantation.胰岛异种移植的进展:免疫屏障、基因编辑进展以及猪到灵长类动物移植中异种胰岛的耐受诱导策略。
Front Transplant. 2022;1. doi: 10.3389/frtra.2022.989811. Epub 2022 Oct 20.
3
Xenotransplantation: Current Challenges and Emerging Solutions.异种移植:当前的挑战与新兴解决方案。
Cell Transplant. 2023 Jan-Dec;32:9636897221148771. doi: 10.1177/09636897221148771.
4
Progress in xenotransplantation: overcoming immune barriers.异种移植的进展:克服免疫障碍。
Nat Rev Nephrol. 2022 Dec;18(12):745-761. doi: 10.1038/s41581-022-00624-6. Epub 2022 Oct 5.
5
Progress in Xenotransplantation: Immunologic Barriers, Advances in Gene Editing, and Successful Tolerance Induction Strategies in Pig-To-Primate Transplantation.异种移植的进展:免疫障碍、基因编辑的进展,以及猪到灵长类动物移植中成功的诱导耐受策略。
Front Immunol. 2022 May 18;13:899657. doi: 10.3389/fimmu.2022.899657. eCollection 2022.
6
Chimerism-Based Tolerance to Kidney Allografts in Humans: Novel Insights and Future Perspectives.嵌合状态诱导的人肾移植免疫耐受:新的见解和未来展望。
Front Immunol. 2022 Jan 5;12:791725. doi: 10.3389/fimmu.2021.791725. eCollection 2021.
7
Mixed xenogeneic porcine chimerism tolerizes human anti-pig natural antibody-producing cells in a humanized mouse model.混合异种嵌合猪嵌合体在人源化小鼠模型中耐受人抗猪天然抗体产生细胞。
Xenotransplantation. 2021 Jul;28(4):e12691. doi: 10.1111/xen.12691. Epub 2021 Apr 26.
8
Intra-bone bone marrow transplantation from hCD47 transgenic pigs to baboons prolongs chimerism to >60 days and promotes increased porcine lung transplant survival.从hCD47转基因猪到狒狒的骨内骨髓移植可使嵌合状态延长至>60天,并提高猪肺移植的存活率。
Xenotransplantation. 2020 Jan;27(1):e12552. doi: 10.1111/xen.12552. Epub 2019 Sep 23.
9
Xenotransplantation tolerance: applications for recent advances in modified swine.异种移植耐受性:改良猪近期进展的应用
Curr Opin Organ Transplant. 2018 Dec;23(6):642-648. doi: 10.1097/MOT.0000000000000585.
10
IXA Honorary Member Lecture, 2017: The long and winding road to tolerance.2017 年 IXA 荣誉会员演讲:通往宽容的漫长曲折之路。
Xenotransplantation. 2018 May;25(3):e12419. doi: 10.1111/xen.12419.

本文引用的文献

1
A murine model of antibody-mediated hyperacute rejection by galactose-alpha(1,3)galactose antibodies in Gal o/o mice.在Gal o/o小鼠中,由半乳糖-α(1,3)半乳糖抗体介导的抗体介导的超急性排斥反应的小鼠模型。
Transplantation. 1998 Sep 27;66(6):754-63. doi: 10.1097/00007890-199809270-00010.
2
Anti-Gal antibody-mediated allograft rejection in alpha1,3-galactosyltransferase gene knockout mice: a model of delayed xenograft rejection.α1,3-半乳糖基转移酶基因敲除小鼠中抗半乳糖抗体介导的同种异体移植排斥反应:一种延迟异种移植排斥反应的模型
Transplantation. 1998 Sep 27;66(6):748-54. doi: 10.1097/00007890-199809270-00009.
3
Adult and neonatal anti-Gal response in knock-out mice for alpha1,3galactosyltransferase.α1,3半乳糖基转移酶基因敲除小鼠的成年和新生期抗半乳糖反应
Xenotransplantation. 1998 Aug;5(3):191-6. doi: 10.1111/j.1399-3089.1998.tb00027.x.
4
Accommodation and T-independent B cell tolerance in rats with long term surviving hamster heart xenografts.长期存活的仓鼠心脏异种移植大鼠中的适应性及非T细胞依赖性B细胞耐受性
J Immunol. 1998 Jan 1;160(1):369-75.
5
Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism.通过诱导混合嵌合体来使抗Galα1-3Gal天然抗体形成B细胞产生耐受。
J Exp Med. 1998 Apr 20;187(8):1335-42. doi: 10.1084/jem.187.8.1335.
6
Alpha-galactosyl epitope-mediated activation of porcine aortic endothelial cells: type I activation.α-半乳糖基表位介导的猪主动脉内皮细胞活化:I型活化
Transplantation. 1998 Mar 27;65(6):844-53. doi: 10.1097/00007890-199803270-00013.
7
Humoral immunity due to long-lived plasma cells.由长寿浆细胞介导的体液免疫。
Immunity. 1998 Mar;8(3):363-72. doi: 10.1016/s1074-7613(00)80541-5.
8
Xenoantigens and xenoantibodies.异种抗原与异种抗体。
Xenotransplantation. 1998 Feb;5(1):6-17. doi: 10.1111/j.1399-3089.1998.tb00003.x.
9
Intravenous infusion of Galalpha1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts.在狒狒中静脉输注α1-3半乳糖寡糖可延缓猪心脏异种移植的超急性排斥反应。
Transplantation. 1998 Feb 15;65(3):346-53. doi: 10.1097/00007890-199802150-00009.
10
Induction of specific transplantation tolerance across xenogeneic barriers in the T-independent immune compartment.在非依赖T细胞的免疫区室中诱导跨越异种屏障的特异性移植耐受。
Nat Med. 1998 Feb;4(2):173-80. doi: 10.1038/nm0298-173.

无需致死预处理诱导的混合嵌合体可防止T细胞和抗α1,3半乳糖介导的移植物排斥反应。

Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection.

作者信息

Ohdan H, Yang Y G, Shimizu A, Swenson K G, Sykes M

机构信息

Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital/Harvard Medical School, Boston 02129, USA.

出版信息

J Clin Invest. 1999 Aug;104(3):281-90. doi: 10.1172/JCI6656.

DOI:10.1172/JCI6656
PMID:10430609
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC408419/
Abstract

Gal alpha 1,3Gal-reactive (Gal-reactive) antibodies are a major impediment to pig-to-human xenotransplantation. We investigated the potential to induce tolerance of anti-Gal-producing cells and prevent rejection of vascularized grafts in the combination of alpha 1,3-galactosyltransferase wild-type (GalT(+/+)) and deficient (GalT(-/-)) mice. Allogeneic (H-2 mismatched) GalT(+/+) bone marrow transplantation (BMT) to GalT(-/-) mice conditioned with a nonmyeloablative regimen, consisting of depleting CD4 and CD8 mAb's and 3 Gy whole-body irradiation and 7 Gy thymic irradiation, led to lasting multilineage H-2(bxd) GalT(+/+) + H-2(d) GalT(-/-) mixed chimerism. Induction of mixed chimerism was associated with a rapid reduction of serum anti-Gal naturally occurring antibody levels. Anti-Gal-producing cells were undetectable by 2 weeks after BMT, suggesting that anti-Gal-producing cells preexisting at the time of BMT are rapidly tolerized. Even after immunization with Gal-bearing xenogeneic cells, mixed chimeras were devoid of anti-Gal-producing cells and permanently accepted donor-type GalT(+/+) heart grafts (>150 days), whereas non-BMT control animals rejected these hearts within 1-7 days. B cells bearing receptors for Gal were completely absent from the spleens of mixed chimeras, suggesting that clonal deletion and/or receptor editing may maintain B-cell tolerance to Gal. These findings demonstrate the principle that induction of mixed hematopoietic chimerism with a potentially relevant nonmyeloablative regimen can simultaneously lead to tolerance among both T cells and Gal-reactive B cells, thus preventing vascularized xenograft rejection.

摘要

α1,3半乳糖基转移酶野生型(GalT(+/+))和缺陷型(GalT(-/-))小鼠联合使用时,α1,3半乳糖(Gal)反应性抗体(Gal反应性抗体)是猪到人的异种移植的主要障碍。我们研究了诱导抗Gal产生细胞耐受并防止血管化移植物排斥的可能性。采用非清髓性方案对GalT(-/-)小鼠进行预处理,该方案包括清除CD4和CD8单克隆抗体、3 Gy全身照射和7 Gy胸腺照射,然后将同种异体(H-2不匹配)GalT(+/+)骨髓移植(BMT)到GalT(-/-)小鼠体内,导致持久的多谱系H-2(bxd) GalT(+/+) + H-2(d) GalT(-/-)混合嵌合体形成。混合嵌合体的诱导与血清抗Gal天然抗体水平的快速降低有关。BMT后2周检测不到抗Gal产生细胞,这表明BMT时预先存在的抗Gal产生细胞迅速被耐受。即使在用含Gal的异种细胞免疫后,混合嵌合体也没有抗Gal产生细胞,并能永久接受供体类型的GalT(+/+)心脏移植物(>150天),而非BMT对照动物在1-7天内排斥这些心脏。混合嵌合体的脾脏中完全没有带有Gal受体的B细胞,这表明克隆缺失和/或受体编辑可能维持B细胞对Gal的耐受性。这些发现证明了一个原理,即采用潜在相关的非清髓性方案诱导混合造血嵌合体可同时导致T细胞和Gal反应性B细胞的耐受,从而防止血管化异种移植物排斥。